Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Director Lewis Clayton Jr. Cantley sold 4,000 shares of the business’s stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $65.59, for a total value of $262,360.00. Following the completion of the sale, the director now owns 86,394 shares in the company, valued at $5,666,582.46. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Lewis Clayton Jr. Cantley also recently made the following trade(s):

  • On Wednesday, September 13th, Lewis Clayton Jr. Cantley sold 1,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $65.47, for a total value of $65,470.00.
  • On Wednesday, August 23rd, Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $56.85, for a total value of $227,400.00.
  • On Wednesday, July 19th, Lewis Clayton Jr. Cantley sold 3,500 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $56.14, for a total value of $196,490.00.
  • On Thursday, July 20th, Lewis Clayton Jr. Cantley sold 9,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $56.36, for a total value of $507,240.00.

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) traded up 1.28% during midday trading on Friday, hitting $66.43. The stock had a trading volume of 863,491 shares. The firm’s market cap is $3.21 billion. Agios Pharmaceuticals, Inc. has a 12 month low of $39.24 and a 12 month high of $67.74. The stock’s 50 day moving average price is $59.96 and its 200 day moving average price is $54.33.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.57) by ($0.21). The business had revenue of $11.30 million for the quarter, compared to the consensus estimate of $10.68 million. Agios Pharmaceuticals had a negative net margin of 502.12% and a negative return on equity of 68.15%. The firm’s revenue for the quarter was up 62.1% compared to the same quarter last year. During the same period last year, the business posted ($1.47) EPS. On average, equities analysts forecast that Agios Pharmaceuticals, Inc. will post ($7.07) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/15/agios-pharmaceuticals-inc-agio-director-lewis-clayton-jr-cantley-sells-4000-shares.html.

A number of institutional investors and hedge funds have recently modified their holdings of AGIO. Teachers Advisors LLC increased its stake in Agios Pharmaceuticals by 22.7% in the 4th quarter. Teachers Advisors LLC now owns 29,592 shares of the biopharmaceutical company’s stock worth $1,235,000 after acquiring an additional 5,467 shares during the last quarter. Bank of Montreal Can increased its stake in Agios Pharmaceuticals by 11.7% in the 1st quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 216 shares during the last quarter. Nationwide Fund Advisors increased its stake in Agios Pharmaceuticals by 5.2% in the 1st quarter. Nationwide Fund Advisors now owns 10,104 shares of the biopharmaceutical company’s stock worth $590,000 after acquiring an additional 500 shares during the last quarter. Janney Montgomery Scott LLC bought a new stake in Agios Pharmaceuticals in the 1st quarter worth approximately $257,000. Finally, Russell Investments Group Ltd. increased its stake in Agios Pharmaceuticals by 163.9% in the 1st quarter. Russell Investments Group Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock worth $149,000 after acquiring an additional 1,583 shares during the last quarter. 94.30% of the stock is currently owned by institutional investors.

A number of equities research analysts recently issued reports on the company. Royal Bank Of Canada assumed coverage on Agios Pharmaceuticals in a research note on Thursday. They issued an “outperform” rating and a $78.00 price objective on the stock. Oppenheimer Holdings, Inc. restated an “outperform” rating and issued a $83.00 price objective (up from $75.00) on shares of Agios Pharmaceuticals in a research note on Thursday, August 10th. SunTrust Banks, Inc. restated a “buy” rating and issued a $80.00 price objective (up from $68.00) on shares of Agios Pharmaceuticals in a research note on Tuesday, August 8th. Leerink Swann upgraded Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $50.00 to $80.00 in a research note on Wednesday, August 2nd. Finally, Cann restated a “buy” rating and issued a $75.00 price objective on shares of Agios Pharmaceuticals in a research note on Sunday, June 11th. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Agios Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $75.11.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.